Background {#Sec1}
==========

Controversies still exist with the concomitant use of clopidogrel, one of the components of the Dual Anti-Platelet Therapy (DAPT) with Proton Pump Inhibitors (PPIs), especially omeprazole following Percutaneous Coronary Intervention (PCI). Even if the American College of Cardiology/Gastroenterology and the American Heart Association recommend prophylactic treatment with a PPI in those patients who require DAPT and those patients who are at high risk of gastrointestinal injury \[[@CR1]\], recent studies have shown clopidogrel and PPIs to be metabolized by the same cytochrome P450 2C19 (CYP2C19) pathway \[[@CR2]\].

Several studies showed no interaction between clopidogrel and PPIs. For example, Rassen et al. showed a slight increase in the rate of Myocardial Infarction (MI) and mortality in older patients discharged on clopidogrel and PPIs, but the authors were not able to conclude any interaction between PPIs and clopidogrel in terms of major clinical relevance \[[@CR3]\]. Zairis et al. also showed no impact of omeprazole on the clinical efficacy of clopidogrel during the first year following PCI \[[@CR4]\].

However, decrease in antiplatelet effects of clopidogrel with the concomitant use of PPIs has been observed. Patients had a higher level of platelet reactivity which resulted in an increased risk of adverse clinical outcomes \[[@CR5]\]. For example, Gupta et al. concluded that the concomitant use of clopidogrel with PPIs following coronary stents implantation was associated with a significantly higher risk of major adverse cardiac events (MACEs) \[[@CR6]\].

In 2012, Huang et al. conducted a meta-analysis based on the current idea, using old data (2009--2011) \[[@CR7]\]. Results from their meta-analysis showed significantly increased risk of MACEs in patients with the concomitant use of clopidogrel and PPIs. Unfortunately, the high level of heterogeneity observed among the different subgroups analyzed was their major limitation.

Recently, many new studies were published based on the cardiovascular outcomes observed in patients treated with clopidogrel plus PPIs and clopidogrel alone following PCI. However, whether these controversies still exist in this new era is not clear. Therefore, we aim to show if the concomitant use of clopidogrel and PPIs is still associated with higher adverse outcomes following PCI using data obtained from recently published studies (2012 to 2016).

Methods {#Sec2}
=======

Data sources and search strategy {#Sec3}
--------------------------------

Three reviewers (P.K.B, A.R.T and A.B) carefully searched EMBASE, PubMed/Medline databases, and the Cochrane library for Randomized Controlled Trials (RCTs) and observational studies comparing the concomitant use clopidogrel with PPI and clopidogrel alone following PCI. The terms 'proton pump inhibitor and clopidogrel', 'proton pump inhibitor and percutaneous coronary intervention' and 'proton pump inhibitor and dual antiplatelet therapy' were searched carefully. In addition, abbreviations such as PPI, PCI and DAPT were also used. In order to widen the search process, individual PPIs namely 'omeprazole, pantoprazole, lansoprazole, esomeprazole, and rabeprazole' were also used in this search strategy. Because this current meta-analysis was based on recently published English articles, and since the previously published meta-analysis already included old data published before or in the year 2011, only studies published after the year 2011 (2012 to 2016) were considered relevant. Unpublished data were not included.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

RCTs and observational studies were included if:They compared patients treated with (clopidogrel and PPIs) and patients treated with clopidogrel but without PPIs following coronary stenting.Adverse cardiovascular outcomes were reported as their clinical endpoints.They were published after the year 2011.

RCTs and observational studies were excluded if:They did not compare patients (clopidogrel and PPIs) with clopidogrel alone following coronary stenting.Adverse cardiovascular outcomes were not reported as their clinical endpoints.They were published before or in the year 2011.They were duplicates.

Outcomes and follow up periods {#Sec5}
------------------------------

Reported outcomes which have been listed in Table [1](#Tab1){ref-type="table"} included:Table 1Reported outcomes and their follow up periodsStudyReported outcomesFollow up periodsType of follow upBhurke 2012 \[[@CR17]\]MI and revascularization9 monthsShort termBurkard 2012 \[[@CR18]\]Death, MI, ST, MACE, TVR3 yearsLong termChitose 2012 \[[@CR19]\]Death, MI18 monthsLong termDouglas 2012 \[[@CR20]\]Death, MI10 monthsShort termDunn 2013 \[[@CR21]\]Death, MI, TVR1 monthShort termGoodman 2012 \[[@CR22]\]Death, MI, ST1 yearLong termHsieh 2015 \[[@CR23]\]MI, revascularization1 yearLong termMacaione 2012 \[[@CR24]\]Death, MI, TVR3 yearsLong termWeisz 2015 \[[@CR25]\]Death, MACEs, MI, ST, TVRIn hospital, 2 yearsShort and long termZou 2014 \[[@CR26]\]Death, MACEs, MI, ST, TVR1 yearLong termGargiolo 2016 \[[@CR16]\]Death, MACEs, MI, ST2 yearsLong term*Abbreviations*: *MI* Myocardial infarction, *ST* Stent thrombosis, *MACEs* Major adverse cardiac events, *TVR* Target vessel revascularization All-cause mortalityMITarget vessel revascularization (TVR)Stent thrombosis (ST)MACEs which consisted of death, MI and repeated revascularization.

Follow up period was divided into a short term follow up period (\<1 year) and a long term follow up period (≥ 1 year).

Data extraction and quality assessment {#Sec6}
--------------------------------------

Three authors (P.K.B, A.R.T and A.B) independently reviewed the data extracted from the studies included in this meta-analysis. Information regarding the type of study, the total number of patients in the study group and the control group respectively, data regarding the baseline characteristics of the patients involved, information regarding the cardiovascular outcomes reported as well as the follow up periods associated with each eligible study were systematically extracted. At a certain point, when the authors disagreed about including certain studies, disagreements were resolved and a final decision was made by the fourth author (W.Q.H). Since only two trials were included in this meta-analysis whereas the other studies were observational cohorts, the risk of bias was not assessed \[[@CR8]\].

Methodological quality and statistical analysis {#Sec7}
-----------------------------------------------

Recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline were followed \[[@CR9]\]. Heterogeneity was assessed using the following:Cochrane Q-statistic test based on a *P* value with a cut-off point of 0.05 whereby a value less or equal to 0.05 was considered statistically significant.I^2^-statistic test whereby an increasing value denoted an increasing heterogeneity.

A fixed effects model (I^2^ \< 50%) or a random effects model (I^2^ \> 50%) was used based on the value of I^2^ obtained.

Odds Ratios (OR) with 95% Confidence Intervals (CIs) were calculated. The pooled analyses were performed with RevMan 5.3 software.

Publication bias was assessed by observing funnel plots. The reason for using funnel plots was the fact that studies with a smaller volume were used. For studies of smaller volumes, due to the higher degree of random changes, they have a wider distribution of results compared to studies of greater volumes. This might cause asymmetry in the funnels whereby publication bias could therefore be visually estimated.

Ethical approval was not necessary for such types of research articles.

Results {#Sec8}
=======

Study selection {#Sec9}
---------------

A total number of 1153 articles were obtained from the searched databases. One thousand and ninety-six articles were rejected since they were either not related to this current topic or they were duplicates. Fifty-seven full text articles were assessed for eligibility. A further six articles were eliminated since they were case studies and meta-analyses. Three more articles were eliminated because their data could not be used (outcomes were reported in terms of Hazard Ratio which was not appropriate to be used in meta-analysis). In addition, 37 more articles were eliminated since they were published before the year 2012. Finally, 11 articles were included in this analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram for the study selection

Baseline characteristics {#Sec10}
------------------------

A total number of 84,729 patients were included in this analysis (29,235 patients treated with clopidogrel plus PPIs and 55,494 patients treated with clopidogrel alone). The general features of the studies have been summarized in Table [2](#Tab2){ref-type="table"}.Table 2General features of the studies includedStudiesNo of patients using clopidogrel + PPIs (*n*)No of patients using clopidogrel alone (*n*)Type of studyRegionBhurke 201229587143RetrospectiveUnited statesBurkard 2012109692RetrospectiveUnited statesChitose 2012187443ObservationalJapanDouglas 20121243916900ObservationalUnited KingdomDunn 20134089191RetrospectiveCharlottesvilleGoodman 201232556021RCTCanadaHsieh 20156705933ObservationalTaiwanMacaione 201212155RetrospectiveItalyWeisz 201521626419ObservationalIsraelZou 201461881465ObservationalChinaGargiolo 20167381232RCTItalyTotal no of patients (*n*)29,23555,494*Abbreviations*: *PPIs* Proton pump inhibitor, *RCT* Randomized controlled trial

Study Douglas 2012, which was conducted in United Kingdom, consisted of the highest number of patients, followed by the studies Bhurke 2012, Dunn 2013 and Goodman 2012 respectively.

The baseline features of the patients have been listed in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} lists the different types of PPIs used by the patients.Table 3Baseline characteristics of the patientsStudyAge (year)Males (%)HT (%)Ds (%)DM (%)CS (%)C + PPI/C aloneC + PPI/C aloneC + PPI/C aloneC + PPI/C aloneC + PPI/C aloneC + PPI/C aloneBhurke 201261.5/59.668.7/76.3\--28.9/26.4-Burkard 201266.5/63.368.8/79.972.5/65.073.4/75.929.6/17.224.8/29.8Chitose 201270.3/68.971.6/72.277.9/79.061.9/61.735.3/33.723.9/26.2Douglas 201271.0/68.058.0/65.0\--34.0/29.016.0/18.0Dunn 201363.9/62.569.3/72.349.5/51.539.4/41.216.5/20.323.9/29.6Goodman 201263.0/62.072.4/71.265.6/65.449.8/45.025.8/24.736.2/35.7Hsieh 201568.4/66.563.6/66.4\-\-\--Macaione 201263.7/65.880.2/87.370.2/81.853.7/58.241.3/49.137.2/27.3Weisz 201564.4/63.270.1/75.983.7/77.876.9/73.234.8/31.422.7/22.6Zou 201466.2/65.773.5/73.971.3/70.460.2/62.325.8/23.632.2/31.0Gargiolo 201671.2/68.172.5/79.272.5/71.353.8/55.323.3/24.822.6/24.4*Abbreviations*: *C* Clopidogrel, *PPI* Proton pump inhibitor, *HT* Hypertension, *Ds* Dyslipidemia, *DM* Diabetes mellitus, *CS* Current smoker Table 4Types of Proton Pump Inhibitors used by the patientsStudiesOmeprazoleEsomeprazoleLansoprazolePantoprazoleRabeprazoleBhurke 201227.123.117.625.86.30Burkard 201217.051.07.0025.0-Chitose 2012\-\-\-\--Douglas 2012\-\-\-\--Dunn 201314.0-18.13.031.60Goodman 201248.911.77.8030.11.48Hsieh 2015\-\-\-\--Macaione 201243.011.610.734.7-Weisz 2015\-\-\-\--Zou 2014\-\-\-\--Gargiolo 20160.50.590.97.600.5Percentage (%) has been used to represent these data

According to the baseline features, there was no significant difference among the patients who were treated with (clopidogrel plus PPIs) and clopidogrel alone.

Main results of this meta-analysis {#Sec11}
----------------------------------

Results of this analysis (summarized in Table [5](#Tab5){ref-type="table"}) showed that during a short term follow up period, using a fixed effects model, mortality and TVR significantly favored clopidogrel alone with OR: 1.55; 95% CI: 1.43--1.68, *P* \< 0.00001 and OR: 1.26; 95% CI: 1.06--1.49, *P* = 0.009 respectively. This result has been represented in Fig. [2](#Fig2){ref-type="fig"}. However, result for the short-term MI which was analyzed using a random effects model, was not statistically significant with OR: 1.17; 95% CI: 0.86--1.58, *P* = 0.32 (Fig. [3](#Fig3){ref-type="fig"}).Table 5Results of the main analysisOutcomes analyzedOR with 95% CI*P* valueI^2^ (%)Short term follow up Mortality1.55 \[1.43--1.68\]0.000010 TVR1.26 \[1.06--1.49\]0.00922 MI1.17 \[0.86--1.58\]0.3291Long term follow up MACEs1.37 \[1.23--1.53\]0.000010 MI1.41 \[1.26--1.57\]0.0000129 ST1.38 \[1.13--1.70\]0.0020 Mortality1.26 \[0.99--1.60\]0.0661 TVR1.28 \[1.01--1.61\]0.0472*Abbreviations*: *OR* Odds ratio, *CI* Confidence interval, *TVR* Target vessel revascularization, *MI* Myocardial infarction, *MACEs* Major adverse cardiac events, *ST* Stent thrombosis Fig. 2Short term adverse clinical outcomes associated with the concomitant use of clopidogrel and PPIs Fig. 3Short term Myocardial Infarction associated with the concomitant use of clopidogrel and PPIs

During the long-term follow up period, MACEs, MI and ST significantly favored clopidogrel alone with OR: 1.37; 95% CI: 1.23--1.53, *P* \< 0.00001, OR: 1.41; 95% CI: 1.26--1.57, *P* \< 0.00001 and OR: 1.38; 95% CI: 1.13--1.70, *P* = 0.002 respectively (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Long term adverse clinical outcomes associated with the concomitant use of clopidogrel and PPIs

However, since a high level of heterogeneity was observed when analyzing the long-term mortality and TVR, a random effects model was used. Long term TVR also significantly favored the non-PPI group with OR: 1.28; 95% CI: 1.01--1.61, *P* = 0.04 whereas the result for the long-term mortality was not statistically significant with OR: 1.26; 95% CI: 0.99--1.60, *P* = 0.06 (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Long term mortality and TVR associated with the concomitant use of clopidogrel and PPIs

Based on a visual inspection of the funnel plot, there has been a low evidence of publication bias among the studies that assessed several subgroups of adverse cardiovascular endpoints. These funnel plots have been illustrated in Fig. [6a and b](#Fig6){ref-type="fig"}.Fig. 6**a** and **b** Funnel plots showing publication bias

Discussion {#Sec12}
==========

Controversies still exist with the concomitant use of clopidogrel and PPIs following coronary stenting, which remain to be solved in this new era. In this analysis, we aimed to compare the adverse clinical outcomes associated with the concomitant use of clopidogrel and PPIs versus clopidogrel alone following PCI using data obtained from recently published articles (2012--2016).

This current analysis showed that during a short term follow up period, mortality and revascularization were significantly lower in those patients who did not require treatment with PPIs. Moreover, during the long term follow up period, adverse cardiovascular outcomes such as MACEs, ST, MI and TVR significantly favored patients in the non-PPI group. However, result for the long-term mortality was similar manifested in both groups.

The previously published meta-analysis \[[@CR7]\] which included 32 studies with publication date before the year 2012 (29 studies published in English and 3 studies published in Chinese), showed the concomitant use of PPI and clopidogrel to be associated with higher MACEs with OR: 1.27, 95% CI: 1.13--1.42 when a combination of data obtained from randomized trials and observational studies was used. However, pooling data only from randomized trials did not show any increase risk of MACEs with OR: 0.92, 95% CI: 0.53--1.58; *P* = 0.72, I^2^ = 0%. When mortality was analyzed using a random effects model, a significant increase was observed with HR: 1.30, 95% CI: 0.91--1.86. But when a fixed effects model was used to analyze mortality, no significant increase was observed with clopidogrel plus PPI with OR: 0.92, 95% CI: 0.82--1.04.

Several reasons have been suggested for such a result. First of all, PPIs involve the same metabolic pathway (mainly CYP2C19 isoenzyme) with that of clopidogrel \[[@CR10]\]. In other words, by occupying the same metabolic pathway as clopidogrel, PPIs are expected to reduce the antiplatelet effects of clopidogrel. Because PPIs can act as both, inhibitors and substrates of CYP2C19, patients treated with clopidogrel and PPIs are vulnerable to a reduced effectiveness of clopidogrel. This could in turn result in a higher platelet activity following PCI finally causing an increase in adverse clinical outcomes. Gilard et al. were the first ones to show the interaction of clopidogrel and PPIs \[[@CR11]\]. Moreover, PPIs not only showed a high platelet reactivity but also showed an increased inflammatory state due to the rise in the level of interleukins-6 which in turn could increase the occurrence of ischemic events \[[@CR12]\]. However, whether PPIs really have an effect on clopidogrel's antiplatelet effect is still being debated.

Similar to the results of this current analysis, many other previously published studies showed that adverse clinical outcomes were significantly increased in the PPIs group. Gupta et al. concluded that the concomitant use of clopidogrel with PPIs was associated with an increased risk of MACEs following PCI \[[@CR6]\]. In addition, Ho et al. showed increased risk of adverse outcomes with clopidogrel plus PPIs \[[@CR13]\].

However, even if many studies supported these current results, several other studies showed results which were completely different. For example, Rassen et al. showed that although a slight increase in hospitalization due to MI and death was observed in older patients who were prescribed PPIs and clopidogrel together, there was not enough evidence to conclude any major interaction between these 2 drugs \[[@CR3]\]. In the analysis from the Guthrie Health Off-Label Stent (GHOST) Investigators, the authors also concluded that the use of PPIs with DAPT was not associated with any increase in MACEs following PCI \[[@CR14]\]. However, their study had a follow up period of only 6 months. Zairis et al. also showed no impact of omeprazole on the clinical efficacy of clopidogrel during the first year following successful PCI \[[@CR4]\]. However, the authors concluded that further highly powered studies should be conducted to confirm whether or not, omeprazole has any effect on the antiplatelet mechanism of clopidogrel. In addition, the COGENT study also did not observe any apparent interaction between clopidogrel and omeprazole, but however, the authors strictly mentioned that their results did not rule out clinically meaningful differences in adverse cardiovascular outcomes due to the use of PPIs \[[@CR15]\].

Nevertheless, among all the PPIs, omeprazole is considered to have a higher effect on the mechanism of clopidogrel. Other studies did not show any notable inter-reaction among non-omeprazole PPIs and clopidogrel. For example, when pantoprazole was used along with clopidogrel, no increase in adverse events was observed and therefore pantoprazole has been recommended compared to omeprazole in patients treated with clopidogrel. In addition, in a sub-analysis of the randomized PRODIGY trial, it was reported that the concomitant use of PPIs, when clinically indicated, in patients receiving clopidogrel, was not associated with adverse clinical outcomes. However, it should also be noted that only less than 1.5% of the patients used omeprazole while more than 90% of the patients in that particular trial used lansoprazole, suggesting that this type of PPIs might be safer to use with clopidogrel \[[@CR16]\].

Since the adverse clinical events associated with non-omeprazole PPIs and clopidogrel have still not clearly been studied, further research is recommended with these individual PPIs (esomeprazole, rabeprazole, lansoprazole, and pantoprazole). In addition, bleeding events especially gastrointestinal bleeding associated with the concomitant use of clopidogrel with these individual PPIs should also be carefully studied.

A moderate level of heterogeneity was observed among certain subgroups analyzing the cardiovascular outcomes. Only English publications were considered, and articles written in other languages were ignored, therefore, a language bias might most probably be present. Moreover, data obtained from conference abstracts and other unpublished studies were not included. However, since most of the data used in this analysis were obtained from observational studies, it could be one of the reasons contributing to the moderate risk of bias observed. In addition, a high level of heterogeneity could also have been due to the fact that different types of patients were included (chronic stable angina, STEMI, NSTEMI) and the type of stent following PCI was also not taken into consideration; patients implanted with DES and BMS were combined and analyzed.

Novelty in this study is the fact that a lower level of heterogeneity was present among several subgroups compared to the previously published meta-analysis. Moreover, different from other studies which mainly report either short term, mid-term or long term outcomes, this analysis has compared the long term and short term adverse clinical outcomes in patients with and without the concomitant use of clopidogrel and PPIs. In addition, this analysis included data obtained from newly published research articles.

Limitations {#Sec13}
-----------

Several limitations are present. Due to a limited number of patients, the result of this analysis might be affected. Moreover, this analysis involved mainly data obtained from observational studies which might be another limitation, and because of this reason, the bias risk of the studies included in this analysis was not assessed using recommendations from the Cochrane Collaboration. In addition, one study reported death, MI and revascularization together. Since data for each outcome could not be separated, we have included the same data for this particular study in the different subgroups analyzing mortality, MI and TVR. Also, adverse bleeding events (GI bleeding) were not analyzed because only a few studies reported bleeding outcomes, which were also different in each of the study, making it difficult to compare.

Conclusion {#Sec14}
==========

The combined use of clopidogrel with PPIs is still associated with significantly higher adverse cardiovascular events such as MACEs, ST and MI following PCI supporting results of the previously published meta-analysis. However, long-term mortality is not statistically significant warranting further analysis with randomized patients.

DAPT

:   Dual antiplatelet therapy

MACEs

:   Major adverse cardiac events

PCI

:   Percutaneous coronary intervention

PPI

:   Proton pump inhibitor

ST

:   Stent thrombosis
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